Company confirms current published specifications for the two-tablet men's wellness supplement, including 24 mg of zinc and a 1,458 mg multi-botanical blend, while advising consumers to rely on current product labeling for final formulation details
VANCOUVER, British Columbia — September 30, 2026 — Leading Edge Health has issued a 2026 U.S. product information update for Volume Pills, confirming the currently published specifications associated with the men’s daily dietary supplement and clarifying how consumers should interpret historical label records, ingredient information and current packaging.
The update identifies a two-tablet serving containing 24 mg of zinc alongside a 1,458 mg proprietary botanical blend, based on publicly available Volume Pills labeling information. Leading Edge Health said consumers should use the Supplement Facts panel supplied with the product they receive as the final reference for ingredient amounts, directions and warnings because formulations and packaging may be updated independently of older online records.
The company currently describes Volume Pills as a “New and Improved” product within its men’s wellness portfolio. The 2026 specification update is intended to consolidate publicly available formula information into one current product document rather than introduce new therapeutic claims or characterize older ingredient research as evidence for the complete supplement.
“Product information can remain online long after packaging, labels and consumer documentation have been revised,” said Kevin Shaw, Product Head at Volume Pills. “This update is intended to give consumers a straightforward reference point for the specifications currently associated with Volume Pills and to make clear that the label on the product in hand should remain the controlling source.”
Current Published Volume Pills Specifications
Volume Pills is supplied in tablet form with a labeled serving of two tablets. Publicly available Supplement Facts information identifies zinc separately at 24 mg per serving and lists a proprietary botanical combination totaling 1,458 mg.
Ingredients associated with the botanical blend include Arjuna, Ling Zhi, Emblica officinalis, Fucus vesiculosus, Hong Hua Fen, Rou Gui, Tian Men Dong, Xian Mao, Dong Chong Xia Cao, Ku Gua, Solidilin, Drilizen and 4′,5,7-trihydroxyflavone.
The individual quantities assigned to those botanical ingredients are not listed separately in the public record reviewed for the update. Leading Edge Health said that distinction is important when consumers compare product specifications with information they encounter elsewhere online.
The company is not representing the 1,458 mg total as though each botanical contributes an equal amount. A proprietary blend provides the combined weight of the listed ingredients but generally does not allow a consumer to calculate the amount contributed by each component unless those quantities are separately provided.
The update therefore treats the 24 mg zinc figure and the 1,458 mg blend figure as product specifications while keeping ingredient-level research separate from statements about the finished Volume Pills formulation.
Why the Company Is Updating Product Information in 2026
Volume Pills has been marketed for a number of years, and some publicly accessible records associated with the product predate the company’s current 2026 consumer documentation.
One Supplement Facts record referenced in the company’s review was entered into the NIH Dietary Supplement Label Database in 2022. That record remains useful for understanding previously published specifications, but Leading Edge Health said a historical database entry should not automatically be treated as proof that every current production lot uses an unchanged formulation.
For more information, visit the official website VolumePills.com.
The company is therefore advising consumers to distinguish between historical database records, third-party descriptions, archived promotional materials and the physical Supplement Facts panel provided with a current purchase.
This approach is intended to reduce confusion that can arise when older product descriptions remain accessible through search engines after packaging or marketing materials have been updated.
Leading Edge Health said the purpose of the specification update is not to suggest that an older label was incorrect. Instead, the company is establishing a hierarchy of product information in which the current physical package takes precedence when determining serving instructions, ingredient amounts and product warnings.
Zinc Remains the Individually Quantified Nutrient
The publicly available Volume Pills label record lists zinc at 24 mg per two-tablet serving. Zinc is an essential mineral involved in numerous normal physiological processes, including cellular metabolism, protein synthesis, DNA synthesis and normal immune function.[1]
The National Institutes of Health Office of Dietary Supplements lists a Recommended Dietary Allowance of 11 mg of zinc per day for adult men and a tolerable upper intake level of 40 mg per day for adults from food and supplements combined.[1]
Leading Edge Health said the 24 mg product specification should be considered in the context of an individual’s total dietary and supplemental zinc intake rather than interpreted in isolation.
Consumers may obtain zinc from food, multivitamins and other dietary supplements in addition to Volume Pills. The company therefore advises users to review the ingredient panels of other products they consume when calculating overall intake.
The NIH also notes that high supplemental zinc intake over extended periods can interfere with copper absorption and that zinc can interact with certain medications.[1] Those established nutrient considerations are provided as general background rather than as evidence that the Volume Pills formulation treats or prevents a medical condition.
Botanical Blend Retains a Combined Weight Specification
The second principal figure confirmed in the update is the 1,458 mg combined botanical blend.
Unlike zinc, ingredients within the botanical mixture are not assigned separate quantities in the public label information reviewed by the company. Leading Edge Health said the combined figure should therefore be read literally as the total weight of the blend rather than as a measure of any individual botanical.
This distinction is relevant because scientific studies commonly specify the exact preparation and amount being investigated.
For example, a published trial involving a particular quantity of an isolated botanical cannot establish that the same quantity is present in Volume Pills when the individual amount within the proprietary combination is not separately disclosed.
Leading Edge Health said it is retaining this distinction in its 2026 documentation so that ingredient background is not presented as though it were finished-product clinical evidence.
“We want product specifications and research context to answer different questions,” Shaw said. “The label tells consumers what is listed in the product, while a research paper tells readers what investigators studied under a particular set of conditions. Those are related pieces of information, but they are not interchangeable.”
Dong Chong Xia Cao Included in Botanical Blend
Dong Chong Xia Cao is one of the names appearing within the publicly identified botanical ingredients and is commonly associated with cordyceps preparations.
Cordyceps has appeared in human research examining physical performance and other outcomes. One randomized controlled study involving 22 trained male cyclists evaluated three grams per day of a specific CordyMax Cs-4 preparation for five weeks.[2]
The researchers reported no significant improvement over placebo in aerobic capacity or endurance performance.[2]
Leading Edge Health includes the study in its supporting documentation as an example of why ingredient inclusion should not automatically be converted into a product-effect claim.
The trial investigated a specific cordyceps preparation at a defined three-gram dose. Volume Pills’ public blend information does not state how much Dong Chong Xia Cao is present individually, so the research cannot be directly mapped onto the finished formulation.
Ling Zhi and Emblica Officinalis
Ling Zhi, commonly identified as reishi or Ganoderma lucidum, also appears in the botanical information associated with Volume Pills.
Memorial Sloan Kettering Cancer Center summarizes research involving reishi and notes that evidence varies according to the condition, preparation and study being considered.[3]
Leading Edge Health said those references are included only to identify the research background associated with the ingredient.
Emblica officinalis, commonly known as amla or Indian gooseberry, has likewise been evaluated independently.
A randomized, double-blind, crossover placebo-controlled study involving 15 healthy adults examined a 500 mg amla preparation and measured several vascular, metabolic and oxidative-stress-related markers.[4]
That research involved amla as an isolated preparation and did not test Volume Pills. The amount of Emblica officinalis within the product’s combined botanical blend is also not individually disclosed in the public label record.
The company therefore does not treat findings from that study as proof of a particular outcome from Volume Pills.
Arjuna Research Provides Ingredient Background
Terminalia arjuna is another botanical associated with the published Volume Pills formulation.
Research involving Terminalia arjuna has included studies in participants with established cardiovascular conditions. One randomized placebo-controlled study examined 500 mg of Arjuna bark powder in adults with coronary heart disease and evaluated lipid and oxidative-stress measurements.[5]
Those participants, study conditions and doses differ materially from the use of an undisclosed quantity of Arjuna as one ingredient within a multi-component dietary supplement.
Leading Edge Health said the research is included only as contextual information about the botanical and does not establish a medical effect for Volume Pills.
This approach also avoids combining separate ingredient studies into an implied clinical trial of the complete product.
Fucus Vesiculosus and Iodine Context
Fucus vesiculosus, commonly known as bladderwrack, is a brown seaweed ingredient included in the botanical information associated with Volume Pills.
Seaweeds naturally contain iodine, although concentrations can vary considerably between species and individual products.[6]
The National Institutes of Health Office of Dietary Supplements lists an adult tolerable upper intake level of 1,100 micrograms of iodine per day from food and supplements combined.[6]
The Volume Pills public blend specification does not identify an individual Fucus vesiculosus quantity or specify an iodine amount attributable to that ingredient.
For that reason, the company said consumers should avoid estimating an iodine quantity based solely on the presence of bladderwrack in the ingredient list.
The company also recommends relying on the current physical product label for any updated warning or specification information associated with the formulation.
Other Botanical Ingredients Remain Part of the Combined Specification
Additional ingredients associated with the published blend include Rou Gui, Tian Men Dong, Xian Mao, Hong Hua Fen, Ku Gua, Solidilin, Drilizen and 4′,5,7-trihydroxyflavone.
Several of these names come from traditional botanical terminology, while others are ingredient or proprietary names appearing in product information.
Leading Edge Health said the purpose of listing these ingredients in the specification update is to document composition rather than attach individual health outcomes to each component.
Research involving cinnamon, bitter melon or other botanicals may use different plant species, extracts, doses and participant populations. Those differences prevent a study involving one isolated preparation from functioning as direct evidence about a combined multi-ingredient formula.
The company is therefore limiting the 2026 update to current product specifications and selected research context needed to explain how those specifications should be read.
Current Label Takes Priority Over Historical Online Records
One of the central elements of the update is the company’s recommendation that consumers inspect the Supplement Facts panel supplied with their current product.
Historical database entries can provide useful information, but they may remain accessible after manufacturers update packaging or other product materials.
Third-party websites may also reproduce older product information and may not be updated at the same time as a manufacturer’s own documentation.
Leading Edge Health said users should therefore confirm serving size, ingredient amounts, directions and warnings from the package they actually receive before beginning use.
The same principle applies to future changes. If the company updates a formula, package or serving specification after September 2026, the new physical label and current company documentation should supersede older summaries of the product.
General Use and Product Positioning
Leading Edge Health positions Volume Pills as a dietary supplement for adult men within its general men’s wellness portfolio. The company does not characterize Volume Pills as a drug or as a treatment for a diagnosed disease.
Its 2026 product information update does not introduce disease-treatment claims and does not represent individual botanical studies as clinical validation of the finished product. Instead, the update confirms the publicly associated ingredient specifications while explaining the distinction between separately quantified nutrients and ingredients grouped within a proprietary blend.
Consumers with questions about whether a multi-ingredient dietary supplement is suitable for their circumstances should discuss supplement use with an appropriate healthcare professional, particularly when they already use prescription medication or other dietary supplements.
About Leading Edge Health
Leading Edge Health is a Canadian health and wellness company established in 2001 and based in British Columbia. The company develops and distributes dietary supplements and consumer wellness products across several categories, including products designed for adult men’s general wellness.
Volume Pills is part of the Leading Edge Health portfolio and is supplied in tablet form. Current company materials identify the product as “New and Improved” and list zinc together with a multi-botanical proprietary blend.
References
[1] National Institutes of Health, Office of Dietary Supplements — Zinc: Health Professional Fact Sheet.
[2] Parcell AC, Smith JM, Schulthies SS, Myrer JW, Fellingham G. “Cordyceps Sinensis (CordyMax Cs-4) Supplementation Does Not Improve Endurance Exercise Performance.” International Journal of Sport Nutrition and Exercise Metabolism. 2004;14(2):236-242.
[3] Memorial Sloan Kettering Cancer Center — Reishi Mushroom.
[4] Kapoor MP, et al. “Clinical Evaluation of Emblica officinalis in Healthy Human Subjects: Health Benefits and Safety Results From a Randomized, Double-Blind, Crossover Placebo-Controlled Study.” Contemporary Clinical Trials Communications. 2019;17:100499.
[5] Gupta R, Singhal S, Goyle A, Sharma VN. “Antioxidant and Hypocholesterolaemic Effects of Terminalia arjuna Tree-Bark Powder: A Randomised Placebo-Controlled Trial.” Journal of the Association of Physicians of India. 2001.
[6] National Institutes of Health, Office of Dietary Supplements — Iodine: Health Professional Fact Sheet.
Media Contact
Kevin Shaw
Product Head, Volume Pills
Leading Edge Health
300-1095 McKenzie Avenue
Victoria, BC V8P 2L5
Email: support@volumepills.com
Website: volumepills.com
Disclaimer: Volume Pills is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Research referenced in this announcement concerns individual nutrients or botanical ingredients studied independently and should not be interpreted as clinical evaluation of the complete Volume Pills formulation. Consumers should review the Supplement Facts panel supplied with their current product for the most current ingredient, serving and warning information.
